Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2019

Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002

20190605 Transgene publi TG4001 TG6002 EN

Published 5 June 2019
Categorized as 2019, Press release, TG4001, TG6002

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

20190527-PR-Last-patient-TG4010-1L-EN

Published 27 May 2019
Categorized as 2019, Press release, TG4010

Combined General Meeting of May 22, 2019

20190522-TG-AGM-2019-EN

Published 22 May 2019
Categorized as 2019, Press release

Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019

20190513-Resultats-Q1-2019-EN-

Published 13 May 2019
Categorized as 2019, Press release

Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

20190513 PR IND TG4050 EN

Published 13 May 2019
Categorized as 2019, Myvac, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

20190509 PR financial meetings Q2 19

Published 9 May 2019
Categorized as 2019, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019

20190509MISE A DISPO AG – US

Published 9 May 2019
Categorized as 2019, Press release

Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies

20190502 – TG-AZ agreement – ENG

Published 2 May 2019
Categorized as 2019, Invir.IO, Press release

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane. M. Harper, et al. Gynecologic Oncology, April 2019 – Download the article The publication has been featured in The Lancet Oncology and Medpage Today Publication

Published 18 April 2019
Categorized as -others, 2018, 2019, Publication, TG4001, TG6002 (FR)

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

B. Grellier, et al. ESMO-AI 2025 Abstract available on ESMO-AI website – Download the abstract – Download the Poster

Published 18 April 2019
Categorized as -others, 2019, Publication, publication key en, TG4001, TG4001

Posts pagination

Newer posts Page 1 … Page 3 Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu